

UCSF

UC San Francisco Previously Published Works

Title

Correction: Study Protocol for PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity.

Permalink

<https://escholarship.org/uc/item/70d9w1k3>

Journal

Cureus, 17(1)

ISSN

2168-8184

Authors

OConnor, Sorcha
Godfrey, Kate
Reed, Sara
[et al.](#)

Publication Date

2025

DOI

10.7759/cureus.c209

Peer reviewed

Erratum: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT_{2A} Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'

Article published 01/29/2025

Article corrected 01/30/2025

Sorcha O'Connor¹, Kate Godfrey¹, Sara Reed², Joseph Peill¹, Cyrus Rohani-Shukla¹, Mairead Healy³, Trevor Robbins³, Ana Frota Lisboa Pereira de Souza⁴, Robin Tyacke¹, Maria Papasyrou¹, Dea Stenbæk⁵, Pedro Castro-Rodrigues⁶, Martina Chiera⁷, Hakjun Lee¹, Jonny Martell¹, Robin Carhart-Harris⁸, Luca Pellegrini^{9, 10}, Naomi A. Fineberg^{11, 12, 13}, David Nutt¹, David Erritzoe¹

1. Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, GBR 2. Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, GBR 3. Department of Psychology, University of Cambridge, Cambridge, GBR 4. Department of Clinical, Pharmaceutical and Biological Science, University of Hertfordshire, Hatfield, GBR 5. Department of Psychology, University of Copenhagen, Copenhagen, DNK 6. Neuropsychiatry Unit, Champalimaud Foundation, Lisbon, PRT 7. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITA 8. Neurology, University of California, San Francisco, USA 9. Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, ITA 10. Department of Mental Health, Psychiatric Clinic, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), Trieste, ITA 11. School of Life and Medical Sciences, University of Hertfordshire, Hatfield, GBR 12. General Adult Psychiatry, Hertfordshire Partnership University NHS Foundation Trust, Hertfordshire, GBR 13. Department of Psychiatry, Cambridge University Clinical Medical School, Cambridge, GBR

Corresponding author: Sorcha O'Connor, s.oconnor22@imperial.ac.uk

Corresponding author: Sorcha O'Connor

1. Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, GBR 2. Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, GBR 3. Department of Psychology, University of Cambridge, Cambridge, GBR 4. Department of Clinical, Pharmaceutical and Biological Science, University of Hertfordshire, Hatfield, GBR 5. Department of Psychology, University of Copenhagen, Copenhagen, DNK 6. Neuropsychiatry Unit, Champalimaud Foundation, Lisbon, PRT 7. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITA 8. Neurology, University of California, San Francisco, USA 9. Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, ITA 10. Department of Mental Health, Psychiatric Clinic, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), Trieste, ITA 11. School of Life and Medical Sciences, University of Hertfordshire, Hatfield, GBR 12. General Adult Psychiatry, Hertfordshire Partnership University NHS Foundation Trust, Hertfordshire, GBR 13. Department of Psychiatry, Cambridge University Clinical Medical School, Cambridge, GBR

How to cite this erratum

O'Connor S, Godfrey K, Reed S, et al. (January 30, 2025) Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT_{2A} Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'. *Cureus* 17(1): c209. doi:10.7759/cureus.c209

Correction Notice

The psilocybin doses included in the following statement have been corrected: "The most promising investigation was conducted by Moreno et al. in 2006; they found that administering different controlled doses of psilocybin (0.3-0.4 mg/kg)". "(0.3-0.4 mg/kg)" has been corrected to "(0.1-0.3 mg/kg)".

Also, the following text has been corrected to reflect the proper dosage: "10 mg, comparable to the 0.3-0.4 mg/kg dose administered by Moreno et al." This has been changed to: "10 mg, comparable to the lower 0.1 and 0.2 mg/kg doses administered by Moreno et al."